We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available here.
Accept

81% Lower Rate of Chronic Cancer-Related Lymphedema

Chirag Shah, MD, April Zambelli-Weiner, Nicole Delgado, Ashley Sier, Robert Bauserman, Jerrod Nelms

This meta‑analysis comparing bioimpedance spectroscopy versus circumferential measurement includes:

  • 50 lymphedema studies and over 67,000 patients studied
  • Investigated BCRL in breast cancer patients
  • Analyzed impact of prospective monitoring and intervention

Study Findings

Results of meta-analysis comparing the use of Bioimpedance Spectroscopy vs. Circumferential Measurement (tape measure) and Impact of Prospective Monitoring and Intervention for Lymphedema.

81% Lower Rate of Chronic Lymphedema than Circumference Monitoring

This recent meta-analysis confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by 81% when compared to circumference monitoring.

LEARN MORE ABOUT L-Dex

81% Lower Rate of Chronic Lymphedema than Circumference Monitoring

Statistically Lower Rates of Chronic Lymphedema in High-Risk Patients and Short-Term and Long-Term Follow-up

Reduced Rates of Chronic Lymphedema in Short-Term and Long-Term Follow-up

This recent meta-analysis confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by 81% when compared to circumference monitoring.

LEARN MORE

Reduced Rates of Chronic Lymphedema in High-Risk Patients

The benefit is sustained in high-risk subgroups as well as short-term and long-term follow-up. L-Dex monitoring and intervention studies showed a statistically significant reduction in chronic lymphedema in studies with >50% axillary lymph node dissection (ALND), >40% mastectomy, <2 years follow-up, and>2 years follow-up when compared to circumference studies.

DOWNLOAD STUDY

Statistically Lower Rates of Chronic Lymphedema in High-Risk Patients and Short-Term and Long-Term Follow-up

Clinical Practice Guidelines

NCCN Guidelines® recommend patient education and regular monitoring for the early detection of lymphedema.

Learn More

Additional guidelines support early detection and intervention

Testing for Early Lymphedema is Easy

L-Dex® testing with the
SOZO® Digital Health Platform

  • Fast
  • Non-invasive
  • Easy-to-use

Test at any location, review
results on the device or online

  • Hospital
  • Cancer Center
  • Outpatient Clinic
  • Physician Office
  • Rehabilitation
  • Radiology

GET A DEMO

Simple Test

Resources

Oncology Solutions

ImpediMed’s point-of-care oncology solutions can help you deliver targeted, personalized, care to your patients.

LEARN MORE

Lymphedema Prevention Program

Comprehensive program to reduce the impact of lymphedema on cancer patients and reduce cost of care.

LEARN MORE

L-Dex Analysis for Lymphedema

Offer your patients peace of mind. Know their L‑Dex score with the leading technology for point-of-care lymphedema assessment.

LEARN MORE
ImpediMed SOZO Device featuring L-Dex Analysis

SOZO Digital Health Platform

SOZO uses ImpediMed’s BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. SOZO is non-invasive, fast, and easy to use. Results from the 30-second test1 are available immediately providing proactive patient care including early detection of disease progression, treatment monitoring, and patient education.

Contact Us

References

  1. As tested on Android.